Cost-effectiveness of prostate boost with high-dose-rate brachytherapy versus intensity-modulated radiation therapy in the treatment of intermediate-high risk prostate cancer-Reference-Cited by-同舟云学术

Cost-effectiveness of prostate boost with high-dose-rate brachytherapy versus intensity-modulated radiation therapy in the treatment of intermediate-high risk prostate cancer

Published:2018-11 Issue:6 Volume:17 Page:852-857
ISSN:1538-4721
Container-title:Brachytherapy
language:en
Short-container-title:Brachytherapy

Author:

Vu Charles C.,Blas Kevin G.,Lanni Thomas B.,Gustafson Gary S.,Krauss Daniel J.

Publisher

Elsevier BV

Subject

Radiology Nuclear Medicine and imaging,Oncology

Reference19 articles.

1. The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer;Shilkrut;Cancer,2013

2. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer;Hoskin;Radiother Oncol,2012

3. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer

4. ASCENDE-RT: an analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer;Rodda;Int J Radiat Oncol,2017

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Brachytherapy boost improves survival and decreases risk of developing distant metastases compared to external beam radiotherapy alone in intermediate and high risk group prostate cancer patients;Radiotherapy and Oncology;2023-06

2. Trends and variations in utilization and costs of radiotherapy for prostate cancer: A SEER medicare analysis from 2007 through 2016;Brachytherapy;2022-01

3. Outcomes with brachytherapy based dose escalation for gleason 8 versus 9-10 prostate cancer: An NCDB analysis;Urologic Oncology: Seminars and Original Investigations;2021-12

4. Utilization of brachytherapy in Quebec, Canada;Brachytherapy;2021-11

5. Does the sequence of high-dose rate brachytherapy boost and IMRT for prostate cancer impact early toxicity outcomes? Results from a single institution analysis;Clinical and Translational Radiation Oncology;2021-07